Latest / Decera Clinical Education Oncology Podcast
TROP2-Directed Antibody–Drug Conjugates in Non-Small-Cell Lung Cancer: Current Use in Clinical Practice and Future Directions
In this episode, Dr Matthew Gubens and Dr Helena Yu discuss the evolving role of TROP2-directed therapies in non-small-cell lung cancer, with a focus on how antibody–drug conjugates (ADCs) fit into current treatment strategies, including
The mechanism of action and clinical trial outcomes of TROP2-directed ADCs like datopotamab deruxtecan and sacituzumab tirumotecan
Use of these therapies in EGFR-mutant disease and how they fit into a changing treatment landscape
Practical advice on associated adverse events and additional considerations,
A look at future directions on the horizon, such as…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.